vesnarinone has been researched along with Cardiomyopathies in 2 studies
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vesnarinone is a novel oral agent that improves survival and symptoms of patients with dilated cardiomyopathy." | 6.68 | Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy. ( Becker, LC; Feldman, AM; Kasper, EK; Kass, DA; Van Anden, E; White, WB, 1996) |
| "Vesnarinone is a novel oral agent that improves survival and symptoms of patients with dilated cardiomyopathy." | 2.68 | Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy. ( Becker, LC; Feldman, AM; Kasper, EK; Kass, DA; Van Anden, E; White, WB, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsui, S | 1 |
| Matsumori, A | 1 |
| Matoba, Y | 1 |
| Uchida, A | 1 |
| Sasayama, S | 1 |
| Kass, DA | 1 |
| Van Anden, E | 1 |
| Becker, LC | 1 |
| Kasper, EK | 1 |
| White, WB | 1 |
| Feldman, AM | 1 |
1 trial available for vesnarinone and Cardiomyopathies
| Article | Year |
|---|---|
Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy.
Topics: Administration, Oral; Cardiomyopathies; Cardiotonic Agents; Dose-Response Relationship, Drug; Double | 1996 |
1 other study available for vesnarinone and Cardiomyopathies
| Article | Year |
|---|---|
Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.
Topics: Amrinone; Animals; Cardiomyopathies; Cardiovirus Infections; Encephalomyocarditis virus; Female; Imm | 1994 |